Latest news with #ODD
CNBC
5 days ago
- Business
- CNBC
Bank of America says these five stocks have more room to run ahead of earnings
Bank of America said this week it sees a host of companies that are well positioned ahead of earnings. Analysts named stocks like Amazon that have compelling valuations or expected catalysts as quarterly reporting season continues. Other buy-rated names it cited include: Anheuser-Busch InBev, Oddity Tech , Bilibili and AppLovin. Oddity Tech The global beauty tech platform is firing on all cylinders, the firm wrote. Analyst Anna Lizzul praised the company's "innovative" digital offering in a recent note and says it has a wide moat for growth. "With the vast majority of its sales direct-to-consumer (DTC) we see ODD at a strategic vantage point to grow with this rise," she wrote. The firm also raised its price target to $80 per share from $68 in advance of the company's earnings report on Aug. 4. "We see ODD well positioned to benefit from the beauty category increasingly moving to online sales as consumers' preferred purchasing channels shift," she went on to say. Shares are up 64% this year. Bilibili Analyst Miranda Zhuang is standing by shares of the China-based online video platform. Bank of America recently attended an investor day and came away feeling even more constructive on the stock. "Management highlighted strategies centering on high-quality content, AI empowerment to content and monetization, long-lifecycle games," she wrote. Zhuang raised her price target on the stock to $27 per share from $25 citing the company's second-quarter earnings report in mid-August as yet another positive catalyst for the stock. "We reiterate our Buy rating given Bilibili's unique platform value proposition, long growth runway, and benefits from AI," Zhuang said. Bilibili shares are up 28% this year. Anheuser-Busch InBev Shares of the alcoholic beverage giant have plenty more room to run, according to the firm. The company is scheduled to report its second-quarter earnings on July 31. "Volume in Q2 will likely be held back, again, by China and the US, but we expect continued margin expansion in Q2, supporting +5.6% organic EBITDA growth," analyst Andrea Pistacchi wrote. However, despite the possible volume decline, the firm says there's plenty of other positive catalysts. "One of the main areas of focus for Q2/H1 results will be share buy backs," he said. Meanwhile, shares of the company are up almost 40% this year. "We continue to like ABI, as one of the most reliable staples compounders," he went on to say. Oddity Tech "An innovative consumer tech platform, ODD utilizes proprietary technology to provide consumers with product recommendations. We see ODD well positioned to benefit from the beauty category increasingly moving to online sales as consumers' preferred purchasing channels shift. ... With the vast majority of its sales direct-to-consumer (DTC) we see ODD at a strategic vantage point to grow with this rise." Bilibili "Management highlighted strategies centering on high-quality content, AI empowerment to content and monetization, long-lifecycle games. ... We reiterate our Buy rating given Bilibili's unique platform value proposition, long growth runway, and benefits from AI. ... We expect 2Q ad business to benefit from good ad spend from ecommerce campaigns and the digital products category." Anheuser-Busch InBev "Volume in Q2 will likely be held back, again, by China and the US, but we expect continued margin expansion in Q2, supporting +5.6% organic EBITDA growth. .... One of the main areas of focus for Q2/H1 results will be share buy backs. ... We continue to like ABI, as one of the most reliable staples compounders." AppLovin "APP remains top pick under coverage. We see big upside to CY26 EBITDA expectations, with this print potentially prompting upward revisions; the vast majority of investors we spoke with appear to exclude both a continued managed service onboarding ramp, and a major self-serve ramp in CY26." Amazon "Expect retail beat, AWS growth in focus for 2nd half. ... We think Amazon's focus on the customers and the buyer experience is right for the Internet. We think Amazon is well positioned to capitalize on the global growth of eCommerce and other secular trends such as cloud computing, online advertising and connected devices." Read more.
NZ Herald
24-07-2025
- NZ Herald
Serial sex offender Luca Fairgray's prison sentence cut on appeal
In June, Fairgray's lawyer Susan Gray told the Court of Appeal that his sentence and its starting point was 'manifestly excessive'. A starting point (for example: four years' prison) is the sentence which a judge decides on before taking into account aggravating or mitigating factors that may increase or reduce a sentence. A judge uses any comparable cases to determine what that starting point is. Gray submitted 'a lack of consistency is a lack of justice' and she pointed to another case where a man who had ongoing sex with one minor and one-off sex with another was given a starting point of 2.5 years in prison. She acknowledged the pregnancy and abortion that occurred because of Fairgray's offending, and its distressing impact, but said it was wrong for the judge to attribute the second surgical intervention needed to her client. Gray also took issue with the Crown's submission that the victim was vulnerable due to her age, as she said it was inherent in the charge. The seven-year age gap between Fairgray and the complainant was at the lower end of the spectrum, she said. 'There was no breach of trust.' Prosecutor Pip McNabb said the real issue before the court was whether the four-year starting point was available to Judge Thomas. She told the Justices the victim's vulnerability was about much more than just her age and included her autism, attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) diagnosis. 'At the lowest end of that seven-year age gap we have a 13-year-old girl, so she had just become a teenager.' At the other end of the spectrum, she said, was an educated 20-year-old male. She did not agree that Fairgray's own diagnoses of autism and ADHD tempered the difference between the pair. His offending was 'calculated and careful', she said, and he actively pursued the girl despite knowing her age. McNabb submitted that while the second surgery could not be directly attributed to the appellant, it was his actions of having unprotected sex with her that led to it. The Crown maintained that there were some efforts by him to manipulate the victim. Luca Fairgray pictured when he testified in the Auckland District Court earlier this year. The three appeal judges hearing the case agreed with Fairgray's lawyer that the starting point taken by the sentencing judge was too high. In its decision, released by Justice Rachel Dunningham this afternoon, the appeal court said there were clearly adverse effects on the victim through having to endure a termination of her pregnancy. 'However, there was no abuse of trust, nor was there a significant age gap (comparatively speaking) between the offender and the victim. There were also no other aggravating features present such as grooming, or abusive or demeaning behaviour. This assessment points to a lower starting point than was adopted in R v H [the case the sentencing judge used as a comparison] and we would adopt three and a half years,' she said. After taking that starting point, the Court of Appeal then added on six months to Fairgray's jail term due to the fact his offending followed crimes of a similar nature (the same uplift imposed by Judge Evangelos Thomas at his sentencing). As a result, the Court of Appeal cut Fairgray's final sentence to four years' jail. Katie Harris is an Auckland-based journalist who covers issues including sexual assault, workplace misconduct, media, crime and justice. She joined the Herald in 2020. Sign up to The Daily H, a free newsletter curated by our editors and delivered straight to your inbox every weekday.
Korea Herald
10-07-2025
- Business
- Korea Herald
IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel
SHANGHAI, NANJING, China and SAN FRANCISCO, July 9, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed anti-BCMA CAR-T cell therapy product, Equecabtagene Autoleucel (Fucaso), has been granted Orphan Drug Designation (ODD) by the Ministry of Food and Drug Safety (MFDS) of South Korea for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. Currently, the Korean MFDS adopts a dual standard for orphan drug designation: 1. Drugs used for diseases with a domestic patient population (prevalence) of 20,000 or fewer; 2. Drugs used for diseases for which appropriate treatment methods or drugs have not been developed, or drugs that demonstrate significantly improved safety or efficacy compared to existing alternative drugs. For orphan drugs that are "available abroad but not domestically", South Korea has policies to facilitate their import*. Following ODD, the registration and approval process of Equecabtagene Autoleucel Injection in South Korea is expected to be accelerated, potentially enabling earlier access for local patients. Ms. Jinhua Zhang, Founder, Chairwoman, and CEO of IASO Biotherapeutics, stated: "The Orphan Drug Designation granted to Equecabtagene Autoleucel Injection in South Korea marks another significant international regulatory milestone for the product, following its ODD approval in Saudi Arabia in May. This Designation is expected to accelerate patient access to this CAR-T therapy in South Korea. IASO Bio is implementing its global registration strategy of 'parallel multi-country submissions with regional synergy'to obtain approvals for this innovative cell therapy in additional countries and regions, ultimately extending its benefits to a wider patient population." About Multiple Myeloma（MM) Multiple myeloma (MM) is the second most common hematological malignancy globally. According to Globocan data, the global incidence of multiple myeloma in 2022 was 1.8 per 100,000 people, with a 5-year prevalence of 6.8 per 100,000. Despite progress in current anti-myeloma treatments, MM remains largely incurable with multiple relapses and tendency to develop refractoriness to several drug classes, presenting a major therapeutic challenge. Thus, there is an unmet need for new treatment options beyond these current anti-myeloma therapies for the treatment of relapsed or refractory MM, capable of achieving deep and durable responses. About Equecabtagene Autoleucel（Fucaso） Equecabtagene Autoleucel（Fucaso） is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane domain, and 4-1BB co-stimulatory molecule and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations, Fucaso demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve deep and durable remission,providing continuous protection and care for patients with multiple myeloma. About IASO Bio IASO Bio is a biopharmaceutical company focused on the discovery and development of innovative cell therapies and biologics for oncology and autoimmune diseases. IASO Bio possesses comprehensive capabilities spanning the entire drug development process, from early discovery to clinical development, regulatory approval, and commercialization. Its pipeline includes a diversified portfolio of over 10 novel products, including Equecabtagene Autoleucel (a fully human BCMA CAR-T injection). Equecabtagene Autoleucel received Biologics License Application (BLA) approval from China's National Medical Products Administration (NMPA) in June 2023and U.S. FDA IND approval for the treatment of R/RMM in December 2022. Leveraging its strong management team, innovative product pipeline, as well as integrated and high quality manufactural and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfil unmet medical needs to patients in China and around the world. For more information, please visit or
Yahoo
07-06-2025
- Business
- Yahoo
Online Cosmetics Retailer Oddity Draws in Big Money
ODD is an online cosmetics retailer offering its more than 60 million users an AI platform to shop and buy customized cosmetics. The company uses an algorithm to help match users to ideal products. It's emerged as a leader using its online-only strategy and its Il Makiage and Spoiled Child brands are gaining in popularity. On the earnings front, ODD's first-quarter fiscal 2025 report showed a 27% revenue increase, to $268 million. Adjusted EBITDA margin was almost at 20%, reflecting a reading of $52 million. The company's lack of debt and cash position of $257 million position it well for the future, as does its guidance. For the full year, ODD raised its gross margin outlook to 71%, adjusted EBITDA to an upward end of $161 million, and adjusted per-share earnings outlook to a high of $2.04. It's no wonder ODD shares are up 83% this year – and they could rise more. MoneyFlows data shows how Big Money investors are betting heavily on the forward picture of the stock. Institutional volumes reveal plenty. In the last year, ODD has enjoyed strong investor demand, which we believe to be institutional support. Each green bar signals unusually large volumes in ODD shares. They reflect our proprietary inflow signal, pushing the stock higher: Plenty of staples names are under accumulation right now. But there's a powerful fundamental story happening with Oddity. Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, ODD has had strong sales and earnings growth: 3-year sales growth rate (+43.3%) 3-year EPS growth rate (+98.6%) Source: FactSet Also, EPS is estimated to ramp higher this year by +18.8%. Now it makes sense why the stock has been powering to new heights. ODD has a track record of strong financial performance. Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term. Oddity has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis. It's made the rare Outlier 20 report multiple times. The blue bars below show when ODD was a top pick…supported by Big Money inflows: Tracking unusual volumes reveals the power of money flows. This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward. The ODD rally isn't new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio. Disclosure: the author holds no position in ODD at the time of publication. If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights. This article was originally posted on FX Empire Portugal: Persistent Political Fragmentation to Test Growth and Fiscal Prospects US Foods Seeing Inflows Market Outlook: Crypto Trading Big Money Buys LPL Financial Shares Should You Invest in European Stocks Now? Big Money Keeps Buying Palantir
Yahoo
16-05-2025
- Business
- Yahoo
Conneaut pursuing comprehensive zoning reform
CONNEAUT — The city is looking to conduct a comprehensive zoning reform this year, City Manager Nick Sanford said. He said the city identified the need for zoning reform in an update to its comprehensive plan in 2018. 'Our zoning text by and large dates back in 1982,' Sanford said. The city needs to update its zoning codes to reflect the fact it is not 1982 anymore, he said. 'Our zoning code's just old, frankly,' he said. City leadership is interested in reforms that work out for both residents and developers, Sanford said. Sanford is interested in having the zoning districts have more flexibility for development and applications for development, while working to preserve historic buildings in the city, he said. Sanford said the update has to focus on the fact Conneaut is geographically diverse, with a coastline and rural and urban areas. 'It's imperative that we are mindful of that,' he said. Sanford was thankful for the work of previous city administrations and councils for what they could do to pursue the issue, despite the COVID-19 pandemic, he said. Sanford is interested in having the zoning reforms done by the end of the year, he said. 'I think it's an achievable goal,' he said. The city is still in the early stages of the project, Sanford said. 'We're essentially testing waters to get started in this,' he said. Sanford said he wants to have community workshops to hear from residents. None are planned yet, he said. The city was interested in getting a grant from the Ohio Department of Development to fund the project. Council passed a resolution approving the grant application at an April 28 meeting. Sanford said ODD received around $2 million in requests, and had to close the window for funding applications early. 'This is something we're still going to pursue without funding,' he said. Sanford said MS Consultants, an engineering firm the city uses, has several employees versed in the nuances of zoning reform and law, who can help the city.
